Chondroitin Sulfate Proteoglycan 4 Specific Chimeric Antigen Receptor Therapy for Pediatric Solid Tumors

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-2-s3-p39
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Molecular Therapy - Oncolytics
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

Prospects to Improve Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Immunotherapy
OncologyAllergyImmunology
2016English

Chondroitin Sulfate Proteoglycan (CSPG)

Science-Business eXchange
2014English

Chondroitin Sulfate Proteoglycan CSPG4 as a Novel Hypoxia-Sensitive Marker in Pancreatic Tumors

PLoS ONE
Multidisciplinary
2014English

394. McSP-Chimeric Antigen Receptor (CAR)-Redirected T Cells Target Multiple Solid Tumors

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2013English

212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2018English

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

International Journal of Hematology
Hematology
2020English

Targeted Downregulation of N-Acetylgalactosamine 4-Sulfate 6-O-Sulfotransferase Significantly Mitigates Chondroitin Sulfate Proteoglycan-Mediated Inhibition

GLIA
Molecular NeuroscienceNeurologyCellular
2011English

Histochemical Differentiation Between Chondroitin 4-Sulfate and Chondroitin 6-Sulfate.

Kurume Medical Journal
Medicine
1978English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy